Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zur Bewertung der Sicherheit und Verträglichkeit von GEH200520/GEH200521 (18F) bei der Verwendung für PET-Scans bei Patienten mit bösartigen Tumoren

22. September 2026 aktualisiert von: GE Healthcare

Eine multizentrische, offene Dosiseskalations- und Dosisexpansionsstudie der Phase 1a/1b bei Patienten mit malignen soliden Tumoren zur Bewertung der GEH200520-Injektion / GEH200521 (18F) Injektionssicherheit und -verträglichkeit, PET-Bildgebung, Pharmakokinetik und Veränderungen in Bildgebung nach der Behandlung

Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days.

Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment.

Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunotherapy immune-checkpoint inhibitor (ICI) treatment visits and 2 additional imaging and 1 follow-up visit. Two late imaging transfer expected post follow up visit. The estimated duration for subject participation in Part B is approximately 64 days.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

19

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Amsterdam, Niederlande
        • Amsterdam UMC
      • Groningen, Niederlande
        • UMC Groningen

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • The subject is able and willing to comply with all study procedures as described in the protocol, including the imaging day pre-visit requirements, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
  • The subject is male or female, ≥18 years of age.
  • Subject has a life expectancy ≥12 weeks.
  • Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Subject has an unresectable or metastatic solid tumour or a local and resectable head and neck squamous cell carcinoma, or an unresectable stage III-IV melanoma.
  • Subject is eligible for ICI treatment per Investigator judgement.
  • Subject has at least 1 measurable tumour lesion documented on CT/magnetic resonance imaging (MRI) RECIST v1.1 during the last 12 months.
  • Subject has a tumour lesion(s) of which a biopsy can safely be obtained according to standard clinical care procedures.
  • Subject is male or female that agrees to adhere to the protocol contraception methods.

Exclusion Criteria:

  • Subject is unable to undergo all procedures in the study and/or is unable to remain still and tolerate the imaging procedure.
  • Subject has 12-lead ECG significant findings during screening, per Investigator's assessment.
  • Subject is not stable due to medical condition or therapy that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents.
  • Subject has serious non-malignant disease or conditions that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has B or T cell lymphoma.
  • Subject has brain or bone-marrow metastasis that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has signs or symptoms of systemic infection within 2 weeks prior to imaging day.
  • Subject has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins or known allergy to the study IMP ingredients and/or the proposed ICI therapy.
  • Subject has any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the ICI treatment, or that may affect the interpretation of the results or render the subject at high risk from complications.
  • Subject has laboratory values out of range per protocol.
  • Subject has any safety laboratory test results (blood chemistry, haematology, and urinalysis) that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has had any major surgery within 4 weeks prior to enrollment.
  • Subject has been enrolled in another interventional clinical study within the 30 days before screening for this study, except for the study site IIS.
  • Subject is pregnant or planning to become pregnant or is breastfeeding.
  • Subject has a history of alcohol or drug abuse within the last year.
  • Subject has had treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to dosing with the IMP.
  • Subject has had treatment with systemic immunosuppressive medications within 2 weeks prior to dosing with the IMP.
  • Subject has received acute, low-dose, systemic immunosuppressant medications that, in the opinion of the Investigator, could compromise protocol objectives.
  • Subject has used systemic corticosteroids to treat inflammatory or autoimmune symptoms.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Diagnose
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Part A Cohort 1 - 1 mg dose

1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 2 - 2 mg dose

2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 3 - 4 mg dose

4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 4 - 8 mg dose

8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 5 (optional) - 12 or 15 mg dose

12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 6 - Optimal dose

Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part B

Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Teil A: Die Inzidenz von UEs nach Kausalität zu den IMPs.
Zeitfenster: Teil A: 7 Tage
Teil A: 7 Tage
Teil A: Der Schweregrad von UE gemäß den Common Terminology Criteria for Adverse Events des National Cancer Institute (NCI CTCAE Version 5.0) nach Kausalität für die IMPs.
Zeitfenster: Teil A: 7 Tage
Teil A: 7 Tage
Bewertung der Zeitverlaufsänderungen bei der Injektionsaufnahme von GEH200521 (18F) nach Behandlungszyklen mit Immun-Checkpoint-Inhibitoren (ICI) im Vergleich zum Ausgangswert.
Zeitfenster: Teil B: 50 Tage
Teil B: 50 Tage

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Bewertung der Strahlendosimetrie einer festen Dosis von GEH200521 (18F)-Injektion bei Verabreichung mit verschiedenen GEH200520-Injektions-Massendosen nach kumulierter Aktivität in Quellregionen und am ganzen Körper.
Zeitfenster: 7 Tage
7 Tage
Bewertung des optimalen Bildgebungszeitfensters für GEH200521 (18F) Injektions-Positronen-Emissions-Tomographie (PET)-Bildgebung bei Verabreichung verschiedener GEH200520-Injektionsmassendosen für Probanden aus Teil A.
Zeitfenster: 7 Tage
7 Tage
Zur Bestimmung der geeigneten Massendosis von GEH200520 Injektion zur Verabreichung mit GEH200521 (18F) Injektion, um eine akzeptable PET-Bildqualität für Probanden aus Teil A zu erreichen.
Zeitfenster: 7 Tage
7 Tage
Zur Beurteilung der Immunogenität anhand des Auftretens von behandlungsinduzierten Anti-Drogen-Antikörperreaktionen nach einer einzelnen Injektion der verschiedenen GEH200520-Injektionsmassendosen, die mit einer festen Dosis von GEH200521 (18F)-Injektion für Probanden aus Teil A verabreicht wurden.
Zeitfenster: 7 Tage
7 Tage
Erfassung von Inzidenz, Schweregrad, Veränderungen zwischen Visiten für UEs/SAEs/UESIs
Zeitfenster: 50 Tage
50 Tage
Bewertung der Bioverteilung und Tumoraufnahme von GEH200521 (18F)-Injektion mit der optimalen GEH200520-Injektionsdosis, die in Teil A basierend auf quantitativen Messungen von GEH200521 (18F) in interessierenden Regionen für Probanden aus Teil B bestimmt wurde.
Zeitfenster: 50 Tage
50 Tage
Bewertung der Beziehung zwischen der Tumor-GEH200521 (18F)-Injektionsaufnahme (SUV-Wert) und dem CD8+-Expressions-Score von Immunzellen aus einer Biopsieprobe/resezierten Läsion, sofern verfügbar, basierend auf IHC-Ergebnissen für Probanden aus Teil B.
Zeitfenster: 50 Tage
50 Tage
Zum Vergleich von Änderungen in der Injektionsaufnahme des Tumors GEH200521 (18F) mit Änderungen in der Computertomographie (CT)-Bildbeurteilung gemäß Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 für Probanden in Teil B, sofern verfügbar.
Zeitfenster: 50 Tage
50 Tage
Zum Vergleich von Änderungen in der Tumor-GEH200521 (18F)-Injektionsaufnahme mit Änderungen in der Computertomographie (CT)-Bildbeurteilung gemäß [18F]-Fluordeoxyglukose (FDG)-Scans, sofern verfügbar für Probanden aus Teil B.
Zeitfenster: 50 Tage
50 Tage
Vergleich der Immunogenität anhand der Inzidenz von behandlungsinduzierten Anti-Drogen-Antikörperreaktionen nach mehrfacher Verabreichung von GEH200520-Injektion mit GEH200521 (18F)-Injektion für Probanden aus Teil B.
Zeitfenster: 50 Tage
50 Tage
To characterize the pharmacokinetic (PK) properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Zeitfenster: 7 days

The PK parameter to be assessed: AUC

7 days
To characterize the pharmacokinetic (PK) properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Zeitfenster: 7 days

The PK parameter to be assessed: Cmax

7 days
To characterize the pharmacokinetic (PK) properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Zeitfenster: 7 days

The PK parameter to be assessed: CL

7 days
To characterize the pharmacokinetic (PK) properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Zeitfenster: 7 days

The PK parameter to be assessed: V

7 days
To characterize the pharmacokinetic (PK) properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Zeitfenster: 7 days

The PK parameter to be assessed: t1/2

7 days
Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs, for Part A subjects.
Zeitfenster: 7 days

Incidence of AEs, SAEs, and Treatment-emergent AEs by system organ class and preferred term

7 days
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Zeitfenster: Baseline, 24 hours, 7 days post IMP administration

The findings in the physical exam pre and post-administration will be summarized.

Baseline, 24 hours, 7 days post IMP administration
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Zeitfenster: Baseline, 24 hours, 7 days post IMP administration

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, 24 hours, 7 days post IMP administration
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Zeitfenster: Baseline, 24 hours, 7 days post IMP administration

Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.

Baseline, 24 hours, 7 days post IMP administration
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Zeitfenster: Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration heart rate values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Zeitfenster: Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration blood pressure values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Zeitfenster: Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration body temperature values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Zeitfenster: Baseline, 2 hours, 24 hours, 7 days post IMP administration

Descriptive statistics will be used to describe the observed values and change from baseline.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Zeitfenster: Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration physical exam status values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Zeitfenster: Baseline, Day 15, Day 36, Day 50

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Zeitfenster: Baseline, Day 15, Day 36, Day 50

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Zeitfenster: Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration heart rate values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Zeitfenster: Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration blood pressure values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Zeitfenster: Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration body temperature values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Zeitfenster: Baseline, Day 15, Day 36, Day 50

Descriptive statistics will be used to describe the observed values and change from baseline.

Baseline, Day 15, Day 36, Day 50
To characterize the PK properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Zeitfenster: 50 days

The PK parameter to be assessed: AUC

50 days
To characterize the PK properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Zeitfenster: 50 days

The PK parameter to be assessed: Cmax

50 days
To characterize the PK properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Zeitfenster: 50 days

The PK parameter to be assessed: CL

50 days
To characterize the PK properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Zeitfenster: 50 days

The PK parameter to be assessed: V

50 days
To characterize the PK properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Zeitfenster: 50 days

The PK parameter to be assessed: t1/2

50 days

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Ravi Karra, MD, GE Healthcare

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

27. Januar 2023

Primärer Abschluss (Tatsächlich)

4. August 2026

Studienabschluss (Tatsächlich)

4. August 2026

Studienanmeldedaten

Zuerst eingereicht

11. Oktober 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. November 2022

Zuerst gepostet (Tatsächlich)

29. November 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

25. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • GE-269-001
  • 2024-515218-42-00 (Ctis)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .